Lack of association of CYP1A1 polymorphism with prostate cancer susceptibility of Tunisian men

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 7, 2012, Pages 661-666

  Souiden, Yousra ^a,b   Mahdouani, Manel ^a   Chaieb, Kamel ^b   Bakhrouf, Amina ^b   Mahdouani, Kacem ^a,b  

^a Hospital of Ibn Eljazzar of Kairouan   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1;

ADULT; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SUSCEPTIBILITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TOBACCO;

ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 CYP1A1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PREVALENCE; PROSTATIC NEOPLASMS; RISK FACTORS; SMOKING; TUNISIA;

NICOTIANA TABACUM;

EID: 84863930597     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0212     Document Type: Article

References (48)

1. Acevedo C, Opazo JL, Huidobro C, et al. (2003) Positive correlation between single or combined genotypes of CYP1A1 and GSTM1 in relation to prostate cancer in Chilean people. Prostate 57:111-117. (Pubitemid 37204491)
2. [ACS] American Cancer Society (2004) Cancer Facts and Figures. ACS, Atlanta, GA.
3. Aktas D, Hascicek M, Sozen S, et al. (2004) CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Genet Cytogenet 154:81-85. (Pubitemid 39286179)
4. Berndt SI, Chatterjee N, Huang WY, et al. (2007) Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16:165-168. (Pubitemid 46174281)
5. Brossner C, Bayer G, Maderbacher S, et al. (2000) Twelve prostate biopsies detect significant cancer volumes (>0.5 mL). BJU Int 85:705-707. (Pubitemid 30192839)
6. Cavalieri EL, Rogan EG (2010) Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers. Future Oncol 6:75-91.
7. Chang BL, Zheng SL, Isaacs SD, et al. (2003) Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer 106:375-378. (Pubitemid 36870399)
8. Cosma G, Crofts F, Taioli E, et al. (1993) Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Envion Health 40:309-316. (Pubitemid 23344356)
9. Crofts F, Taioli E, Trachman J, et al. (1994) Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963.
10. Crofts R, Cosma GN, Taioli E, et al. (1993) A novel, CYP1A1 gene polymorphism in African-Americans. Carcinogeensis 14:1729-1731. (Pubitemid 23290880)
11. Ferlay J, Bray F, Pisani P, et al. (2001) Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC Press, Lyon. Available at www.iarc.fr/globocan/glo-bocan.html.
12. Gaikwad NW, Yang L, Pruthi S, et al. (2009a) Urine biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer Basic Clin Res 3:1-8.
13. Gaikwad NW, Yang L, Weisenburger DD, et al. (2009b) Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the etiology of non-Hodgkin lymphoma. Biomarkers 14:502-512.
14. Garte S, Gaspari L, Alexandrie AK, et al. (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10:1239-1248. (Pubitemid 34027754)
15. Hefler LA, Tempfer CB, Grimm C (2004) Oestrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 101:264-269. (Pubitemid 38890828)
16. Heidenreich A, Bellmunt J, Bolla M, et al. (2011) Eau guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol 59:61-71.
17. Hsing A, Tsao L, Devesa S (2000) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85:60-67.
18. Hsing AW, McLaughlin JK, Schuman LM, et al. (1990) Diet, tobacco use, and fatal prostate cancer: results from a Lutheran Brotherhood Cohort Study. Cancer Res 50:6836-6840. (Pubitemid 20361078)
19. Jemal A, Siegel R, Ward E, et al. (2006) Cancer Statistics, 2006. CA Cancer J Clin 56:106-130.
20. Karatzas A, Giannatou E, Tzortzis V, et al. (2010) Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men. Cancer Epidemiol 34:345-349.
21. Katoh T, Inatomi H, Kim H, et al. (1998) Effects of glutathione S-transferases GSTM1 and GSTT1 genotypes on urothelial cancer risk. Cancer Lett 132:147-152. (Pubitemid 28535197)
22. Kawajiri K, Nakachi K, Imai K, et al. (1990). Identification of genetically high risk individuals to lung cancer by DNA polymorphism of cytochrome P4501A1 gene. FEBS Lett 263:131-133. (Pubitemid 20107795)
23. Kelada SN, Kardia SL, Walker AH, et al. (2000) The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking. Cancer Epidemiol Biomarkers Prev 9:1329-1334. (Pubitemid 32044801)
24. Kumar V, Singh S, Yadav CS, et al. (2010) CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol 29:126-130.
25. Lathrop G (1983) Estimating genotype relative risks. Tissue Antigens 22:160-166. (Pubitemid 13038101)
26. Latil AG, Azzouzi R, Cancel GS (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92:1130-1137. (Pubitemid 32861661)
27. Lima-Jr MM, Oliveira MN, Granja F, et al. (2008) Lack of association of GSTT1, GSTM1, GSTO1, GSTP1 and CYP1A1 polymorphisms for susceptibility and outcome in Brazilian prostate cancer patients. Folia Biol 54:102-108.
28. Lotufo PA, Lee IM, Ajani UA, et al. (2000) Cigarette smoking and risk of prostate cancer in the physicians' health study (United States). Int J Cancer 87:141-144. (Pubitemid 30368428)
29. Lu F, Zahid M, Saeed M, et al. (2007) Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J Steroid Biochem Mol Biol 105:150-158. (Pubitemid 47211948)
30. Lumey H (1996) Prostate cancer and smoking: a review of case-control and cohort studies. Prostate 29:249-260.
31. Markushin Y, Gaikwad N, Zhang H, et al. (2006) Potential bio-marker for early risk assessment of prostate cancer. Prostate 66:1565-1571. (Pubitemid 44465821)
32. Ming LI, Tong-yu G, Yao LI, et al. (2008) Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men. Chin Med J 121:305-308.
33. Murata M, Shiraishi T, Fukutome K, et al. (1998) Cytochrome P450 1Al and glutathione S-transferase Ml genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol 28:657-660. (Pubitemid 128523207)
34. North AB, South CD (2007) Cancer incidence in Antartica (1998-2002). In: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds) Cancer Incidence in Five Continents. IARC Scientific Publications No. 160. IARC, Lyon, Vol. IX, pp 574.
35. Parkin DM, Bray F, Ferlay J, et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. (Pubitemid 40372904)
36. Quiñ ones LA, Irarrázabal CE, Rojas CR, et al. (2006) Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J Androl 8:349-355.
37. Silig Y, Pinarbasi H, Gü nes S, et al. (2006) Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest 24:41-45. (Pubitemid 43247272)
38. Sivaraman L, Leatham MP, Yee J, et al. (1994) CYP1A1 genetic polymorphism and in situ colorectal cancer. Cancer Res 54:3692-3695. (Pubitemid 24241180)
39. Song N, Tan W, Xing D, et al. (2001) CYP1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis 22:11-16. (Pubitemid 32098138)
40. Suzuki K, Matsui H, Nakazato H (2003) Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study. Cancer Lett 195:177-183. (Pubitemid 36588967)
41. Taioli E, Trachman J, Chen X, et al. (1995) A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 55:3757-3758.
42. Thompson IM, Pauler DK, Goodman PJ, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter. N Engl J Med 350:2239-2246.
43. Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Letters 227:115-124. (Pubitemid 41174580)
44. Xu X, Kelsey KT, Wiencke JK, et al. (1996) Cytochrome p450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5:687-692. (Pubitemid 26304642)
45. Yang L, Gaikwad NW, Meza JL, et al. (2009) Novel biomarkers for risk of prostate cancer: results from a case-control study. Prostate 69:41-48.
46. Zhao Z, Kosinska W, Khmelnitsky M, et al. (2006) Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. Chem Res Toxicol 19:475-479.
47. Zintzaras E, Lau J. (2008a) Trends in meta-analysis of genetic association studies. J Hum Genet 53:1-9.
48. Zintzaras E, Lau J. (2008b) Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61:634-645. (Pubitemid 351766746)